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Any textbook of cardiovascular medicine published within
the past 20 years is sure to contain a lengthy discussion of
the role of dyslipidemia in the development of both athero-
sclerosis and acute arterial thrombosis [1]. Elevated total
serum cholesterol, elevated low-density-lipoprotein choles-
terol (LDL-C), and decreased high-density-lipoprotein cho-
lesterol (HDL-C) are all well-established risk factors for
coronary heart disease [1], while there is still debate about
the contribution of hypertriglyceridemia to this process [2].
Perhaps it is not surprising that major textbooks of hema-
tology [3] and thrombosis medicine [4] do not mention
any role for dyslipidemia in the pathogenesis of venous
thromboembolism (VTE). One reason may be the absence
of pathological evidence of lipid deposition within either
the venous system or the so-called ‘red thrombus’ that
may develop therein [5]. Accordingly, there has been little
hypothesis-generating research exploring the interplay
between lipid dysfunction and VTE. In the following paper,
we discuss the evidence linking hyperlipidemia to the for-
mation of VTE and the possible role of HMG CoA reduc-
tase inhibitors (statins) in its prevention and treatment.
What is the epidemiological evidence linking
dyslipidemia to VTE?
Two cohort [6,7] and six case–control studies [8–13]
have examined the relation between dyslipidemia or serum
lipoprotein (a) [Lp(a)] and VTE. Goldhaber et al retrospec-
tively evaluated several risk factors among 46 adults diag-
nosed with pulmonary embolism at autopsy and 3424
individuals enrolled at baseline in the Framingham Study
[6]. Total serum cholesterol was observed to be a signifi-
cant risk factor for pulmonary embolism in women
(P=0.049), but not men (P > 0.05). In the Nurses’ Health
Study, 280 middle-aged women with a self-reported
history of pulmonary embolism were compared with a
cohort of 112,542 women without a history of pulmonary
embolism [7] (Table 1). They found that those with a self-
reported diagnosis of hypercholesterolemia were at no
increased risk for pulmonary embolism (multivariate rela-
tive risk 1.1, 95% confidence interval [CI] 0.7–1.5).
Kawasaki et al were the first to demonstrate an associa-
tion between hypercholesterolemia and objectively verified
deep vein thrombosis (DVT) of the leg among middle-aged
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Abstract
Recent studies have proposed an association between hyperlipidemia and venous thromboembolism
(VTE). We review the epidemiological evidence linking dyslipidemia with VTE and examine several
possible underlying mechanisms. We discuss the possible role of HMG CoA reductase inhibitors
(statins) in the prevention and treatment of VTE and suggest future directions for research.
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men and women [8]. In comparison with matched con-
trols, the risk for DVT was greatest in the presence of ele-
vated fasting total serum cholesterol, either with or without
concomitant hypertriglyceridemia (Table 1). Among indi-
viduals whose total serum cholesterol was below
5.8 mmol/L, isolated hypertriglyceridemia was not a risk
factor for DVT (odds ratio [OR] 0.9, 95% CI 0.4–2.1).
McColl and colleagues compared 62 women with objec-
tively confirmed VTE before age 50 years with 98 healthy,
age-matched controls and observed a lower mean fasting
total serum cholesterol among cases versus controls
(4.74 versus 5.13 mmol/L, respectively; P < 0.02) [9].
Although the mean LDL-C was also lower among the
cases (2.76 versus 3.18 mmol/L, respectively; P=0.01),
serum triglycerides were slightly higher (1.29 versus
1.09 mmol/L, respectively; P=0.02), and there was no
difference seen for serum Lp(a) (P=0.47).
Two subsequent studies, both of similar design, evaluated
the risk for VTE in the presence of elevated serum Lp(a) in
children [10] and adults [11] (Table 1). In the pediatric
study, an Lp(a) concentration at or above the upper-
quartile value of 30 mg/dL was significantly associated
with VTE, in comparison with the lowest-quartile value. This
effect persisted among a subgroup of children without an
underlying illness (adjusted OR 7.1, 95% CI 2.7–18.6)
[10]. In the study among adults, an Lp(a) concentration
greater than 30 mg/dL was also associated with VTE [11],
even after adjustment for the presence of other common
thrombophilia risk factors (adjusted OR 2.8, 95% CI
1.6–4.9) [11]. Furthermore, the risk for VTE in that study
rose linearly with increasing Lp(a) concentrations (Table 1).
In a seventh study, Lp(a) concentrations were measured in
64 patients with previous VTE and 64 matched controls
with either atrial fibrillation or valvular heart disease [12].
The median Lp(a) concentrations were not significantly dif-
ferent between cases and controls (69 versus 83 mg/L,
respectively; P=0.34). An eighth group of investigators
compared plasma Lp(a) concentrations in 40 patients with
chronic thromboembolic pulmonary hypertension, 50
patients with primary pulmonary hypertension, and 50
matched disease-free controls [13]. In that study, median
Lp(a) concentrations were higher in subjects with chronic
thromboembolism (26.7 mg/dL) than in those with either
primary pulmonary hypertension (9.7 mg/dL) or no disease
(7.0 mg/dL) [13].
Although some studies suggest an association between
hyperlipidemia and VTE, their results conflict somewhat. The
degree of precision and moderately high effect size seen in
the three positive studies (Table 1), considered in conjunc-
tion with a 20% or greater prevalence of dyslipidemia
among the cases, suggests that elevated concentrations of
total serum cholesterol and Lp(a) may be important risk
factors for VTE in adults and children. While some studies
used fasting samples, only two described collecting speci-
mens at least 3 months after the initial thrombotic event
[10,11]. Specimen collection remote from the initial VTE
event may be important, since lipids are known to decline in
the presence of acute vascular events, such as VTE or
myocardial infarction [14,15], potentially introducing a nega-
tive confounding effect between dyslipidemia and VTE. In
the two negative cohort studies, their methods for lipid mea-
surement were not reported [6,7], while in the Nurses’
Health Study, recognition of pulmonary embolism and
hypercholesterolemia depended on a self-reported diagno-
sis of both diseases [7], thereby casting some doubt on the
validity of their findings. Future studies could help to clarify
whether dyslipidemia is a causal risk factor for VTE and, if
so, which lipid molecule is most thrombogenic.
Table 1
Epidemiological studies of the associated risk between dyslipidemia and venous thromboembolism (VTE)
Prevalence 
of lipid  Odds
Mean age % cases  risk factor  ratio
No. cases/ of cases  VTE with situational  among (95% CI)
Study [reference] controls (years) type risk factors* Serum lipid risk factor(s) cases (%) for VTE
Goldhaber et al [7] 280/112542 30–55 PE 55 Self-reported elevated TC 18 1.1 (0.7–1.5)
Kawasaki et al [8] 109/109 50 Leg DVT 34 TC > 5.7 mmol/L and TG > 1.7 mmol/L  23 5.1 (2.0–13.0)
TC > 5.7 mmol/L and TG ≤ 1.7 mmol/L 26 2.6 (1.2–5.3)
Nowak-Gottl et al [10] 186/186 5 Any VTE 60 Lp(a) > 30 mg/dL 42 7.2 (3.7–14.5)
von Depka et al [11] 685/266 34 Any VTE 21 Lp(a) > 10 mg/dL 40 1.6 (1.2–2.2)
Lp(a) > 20 mg/dL 25 2.2 (1.5–3.3)
Lp(a) > 30 mg/dL 20 3.2 (1.9–5.3)
*Defined as either immobilization (i.e. trauma, surgery, or bedridden) or presence of an indwelling venous catheter at the site of thrombosis. DVT =
deep vein thrombosis; Lp(a) = lipoprotein (a); PE = pulmonary embolism; TC = total cholesterol; TG = triglycerides; VTE = venous
thromboembolism.c
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Why might lipids induce venous thrombosis?
Before the routine use of acetylsalicylic acid (ASA) and
heparin, patients with acute myocardial infarction previ-
ously experienced high rates of VTE, often independent
of their degree of immobilization during the recovery
period [16–18]. Since then, systemic factors such as
homocysteine [19–21] and antiphospholipid antibodies
[22,23] have been shown to activate the coagulation
cascade or impair the process of fibrinolysis, resulting in
both arterial and venous thrombosis [21,22]. Similarly, if
dyslipidemia is a risk factor for VTE, just as for arterial
thrombosis, then the underlying mechanism is also proba-
bly best conceptualized as a systemic, rather than merely
a depositional or ‘venosclerotic’ [24], disorder within the
vessel wall.
Circulating lipids appear to have both prothrombotic
[25] and endothelium-altering properties [26]. For
example, studies in rats suggest about a 2.3-fold greater
generation of thrombi in hyperlipidemic than normolipi-
demic controls, associated with an 8-fold higher rate of
platelet activation [27]. The thrombogenic potential of
Lp(a) may be explained at several levels. First, the
apolipoprotein B-100 molecule that forms Lp(a) is com-
monly associated with circulating LDL-C and postpran-
dial triglyceride-rich particles [28]. Ingestion of a fatty
meal appears to cause venous endothelial dysfunction in
healthy adults [29], while postprandial lipemia has been
associated with transient changes in factor VII coagulant
(FVII:C) activity in humans [30], suggesting a temporary
and reversible hypercoagulable state [25]. Furthermore,
among individuals with venographically proven DVT,
FVII:C activity was significantly correlated with triglyc-
eride concentrations (r = 0.36,  P=0.021) [31]. Since
neither FVII concentrations, nor the MspI polymorphism
in the FVII gene, are themselves demonstrable risk
factors for VTE [32], perhaps FVII:C requires specific
lipid activation to be thrombogenic, as after the ingestion
of a fatty meal [30].
Lp(a) is also structurally and functionally homologous to
plasminogen, leading to potential competitive binding to
fibrin and hence to impaired fibrinolysis [33]. Of 136 indi-
viduals with ischemic stroke, those with a suspected car-
dioembolic mechanism (i.e. atrial fibrillation or left
ventricular thrombus) had significantly higher concentra-
tions of Lp(a) than those with a noncardioembolic source,
implying a greater association between Lp(a) and acute
arterial thrombosis than between Lp(a) and progressive
atherosclerosis [34]. Thus, it is conceivable that Lp(a) and
associated lipid-rich molecules play a role in the initiation
or progression of VTE. VTE formation occurs through sys-
temic activation of platelets and specific coagulation
factors, in addition to either direct or indirect impairment of
the venous endothelium.
Why might statins reduce the risk of venous
thrombosis?
There now exists a compelling body of evidence for both
early and late benefits of statin therapy in the secondary
prevention of coronary heart disease and stroke [35–38].
Because these agents are also effective in individuals with
‘normal’ baseline lipid measurements [37,38], it has been
suggested that they may also possess antithrombotic [39]
and anti-inflammatory [40] properties.
Recent studies suggest that statins may alter elements
within the vascular endothelium and coagulation cascade
in a manner consistent with an antithrombotic effect. For
example, indirect markers of thrombin generation, such as
prothrombin fragment 1+2, appear to be significantly
reduced after 6 months of pravastatin therapy in women
[41], with a similar effect observed with simvastatin use in
men [42]. One hypothesis to explain these effects is that
these agents inhibit platelet-derived protease-activated
receptor-1 (PAR-1) and tissue factor upregulation, leading
to thrombin generation [43]. Others have demonstrated a
reduction in concentrations of both FVII:C [44] and soluble
thrombomodulin [45] with statin use. There may also be a
rapid biological effect of statins on endothelial barrier per-
meability and nitric oxide production. For example, expo-
sure in vitro of human umbilical vein or aortic endothelial
cell monolayers to simvastatin for 24 hours attenuates
thrombin-induced endothelial barrier dysfunction by 55%.
This effect is related to both the dose and the duration of
drug exposure [46]. Exposure in vitro of isolated human
endothelial cells from the saphenous vein to cervistatin has
also led to a twofold rise in production of both endothelial
nitric oxide synthase and nitric oxide [47].
Once a saphenous vein coronary artery bypass graft
(CABG) is transplanted into the aortocoronary circulation,
it typically takes on certain morphological features akin to
those of native arteries [48]. However, the vessel also
retains some of its original venous properties, and some
venous grafts thrombose within days or weeks of trans-
plantation [48], well in advance of the more common sce-
nario of occlusive ‘venosclerosis’ [24]. This may serve as
an indirect human model for the interplay between dyslipi-
demia, statin use, and venous thrombosis.
For example, in a retrospective series of 212 consecutive
undergoing percutaneous angioplasty of occluded saphe-
nous vein grafts, the most significant risk factor for the devel-
opment of restenosis unstable angina was dyslipidemia
(adjusted OR 3.55, 95% CI 1.64–8.39) [49]. Of the 118
individuals with dyslipidemia, use of lipid-lowering therapy,
principally statins, was associated with a lower risk of resteno-
sis and unstable angina (crude OR 0.41, 95% CI 0.17–0.97).
Dyslipidemia was also found to be a major prognostic
risk factor for saphenous vein graft disease in the Post-
Available online http://cvm.controlled-trials.com/content/2/4/165coronary Artery Bypass Graft (Post-CABG) trial [50].
Among patients randomized to receive high-dose lovas-
tatin (40 mg daily), there was a significant reduction in
both the rate of progression of saphenous vein graft
occlusion and the need for coronary revascularization, in
comparison with patients given low-dose lovastatin
(2.5 mg daily) [51]. Interestingly, lovastatin had no effect
on Lp(a) concentrations, but lipoprotein B concentra-
tions were significantly reduced in the high-dose group
[52]. In a more recent clinical trial, patients with preoper-
ative hypercholesterolemia (total serum cholesterol
greater than 6.2 mmol/L) were randomized to receive
either no therapy (Group 1, n = 37) or 4 weeks of preop-
erative simvastatin, 20 mg daily (Group 2, n = 40). Those
assigned simvastatin continued their therapy for 1 year
postoperatively. Ninety-eight percent of participants
underwent routine follow-up angiography at 1 year. The
rate of detectable graft disease at 1 year, the primary
study endpoint, was 46% in Group 1 and 10% in
Group 2, indicating a benefit with statin therapy (relative
risk 0.30, 95% CI 0.13–0.66). The rate of myocardial
infarction was also significantly higher in Group 1 (5%)
than in Group 2 (0%) (P=0.036). The greatest relative
benefit with statin therapy was observed among those
with saphenous vein grafts [53].
Perhaps the most compelling direct evidence that statins
may reduce the risk for VTE comes from two recent
studies [54,55]. In the Heart Estrogen Replacement Study
(HERS), 1380 women were randomized to hormone
replacement therapy and 1383 women to placebo [54].
During 10,985 woman-years of follow-up, 47 women
developed VTE. In a post-trial analysis, it was found that
statins, but not other lipid-lowering agents, reduced the
risk for VTE by 50% (adjusted hazard ratio [HR] 0.5, 95%
CI 0.2–0.9). The association between statin use and DVT
was also evaluated, in a retrospective Canadian cohort
study comprising 125,862 men and women aged
65 years and older [55]. After 190,601 person-years of
observed drug use, there was an associated decreased
risk of DVT among statin users compared with controls
prescribed thyroid replacement hormones, even after con-
trolling for the presence of cancer, recent hospitalizations,
and ASA or warfarin use (adjusted HR 0.78, 95% CI
0.69–0.87). Just as in the HERS study, nonstatin lipid-
lowering agents did not appear protective against DVT
(adjusted HR 0.97, 95% CI 0.79–1.18). In both studies,
however, the apparent protective effect of statins against
VTE might also be explained by the possibility that statin
users were healthier (i.e. healthy-user bias) or had fewer
VTE risk factors that were not measured.
What further evidence is needed for clinicians?
Dyslipidemia and VTE
We argue that, at present, dyslipidemia should not be
included as part of any thrombophilia work-up in persons
with idiopathic VTE. Consistent epidemiological evidence
is needed to demonstrate that commonly assayed lipids
(e.g. total serum cholesterol, LDL-C, triglycerides), as well
as other lipoproteins [e.g. Lp(a), lipoprotein B], are risk
factors for VTE. In such studies, investigators should con-
sider collecting fasting specimens remote from the time of
the VTE event. Investigators in previous and future epi-
demiological studies and clinical trials designed to evalu-
ate the effect of lipid reduction on cardiovascular disease
might also consider evaluating data on VTE events among
their study participants.
Statins and VTE
Statins cannot be recommended for use in either the pre-
vention or the treatment of VTE. Research studies should
attempt to quantify the risk reduction for VTE with statin
use. A clinical trial aimed at secondary prevention of
recurrent VTE may be one starting point. For example,
patients who have had a first idiopathic VTE and who
have completed 3 or 6 months of anticoagulant therapy
could be randomized to either continue warfarin for
another 12 to 18 months [56] or discontinue their war-
farin and begin on statin therapy. The primary, composite
endpoint of such a trial might be the development of
recurrent VTE or major hemorrhage. Before such a trial
can be justified, more epidemiological evidence is
needed linking statin use to reduced VTE.
A greater understanding is also needed about whether
there is a difference in the antithrombotic properties of
the various statin agents, either in conjunction with, or
independent of, their lipid-lowering properties. For
example, in an audit of 126 individuals with atheroslcero-
sis who switched from simvastatin (mean daily dose
22 mg) to fluvastatin (mean daily dose 37 mg), there was
a significant rise in total serum cholesterol, LDL-C, and
triglycerides, as well as an increase in the subsequent
number of arterial thrombotic events after a mean of 17
weeks [57]. In addition, researchers should focus on
whether statins, in conjunction with drugs such as ASA
[58], may offer an alternative and safe approach to VTE
prevention among individuals at high risk for anti-
coagulant-related hemorrhage.
Conclusion
In summary, there is a new and growing body of epi-
demiological evidence supporting a possible link
between dyslipidemia and the development of VTE, as
well as the potential for statins to reduce the risk of
VTE. The association between both elevated total serum
cholesterol and Lp(a) and VTE is not consistent,
although studies have shown that dyslipidemia is a sig-
nificant risk factor for CABG vein graft occlusion, and
that statins reduce that risk. Finally, preliminary research
suggests that statins may lower the risk for VTE through
several mechanisms.
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